The Influence of Cinobufacin on the Improvement of Syndromes,Serum Tumor Markers and Immune Function in Patients with Advanced Non-small Cell Lung Cancer
Objective:To investigate the effects of cinobufacin on the improvement of syndromes,serum tumor markers and immune function in advanced non-small cell lung cancer(NSCLC)patients.Methods:All 120 patients with advanced NSCLC were divided into 60 cases each in the observation group and the control group using the random number table method.The patients in the control group were treated with chemotherapy,and the patients in the observation group were treated with chemotherapy combined with cinobufacin tablet.To compare the TCM syndrome scores,EORTCQLQ-C30 scores and median survival time of the two groups before and after treatment;to compare the levels of serum tumor markers and immune function indexes of the two groups before and after treatment.Results:The scores of each of the TCM syndromes and EORTCQLQ-C30 scores of patients of the two groups were improved compared with those before treatment,and the patients in the observation group improved better than those in the control group,and the differences were all statistically significant(P<0.05).Therapeutic index of patients in the observation group was higher than that of the control group(P<0.05).The median survival time of the observation group was longer than that of the control group(P<0.05).After treatment,tumor markers such as(carcinoembryonic antigen,CEA),cytokeratin 19 fragment 21-1(CYFRA21-1),and vascular endothelial growth factor(VEGF)were lower in the observation group compared with the pre-treatment period,and the observation group was lower than the control group,and the differences were all statistically significant(P<0.05).After treatment,NK,CD3+,CD4+ and CD4+/CD8+ increased in the observation group compared with the control group and before treatment,and the differences were all statistically significant(P<0.05);NK,CD3+,CD4+ and CD4+/CD8+ decreased in the control group compared with the pre-treatment period,and the differences were statistically significant(P<0.05).Conclusion:Treatment of advanced NSCLC patients with cinobufacin can improve TCM syndromes,lower the levels of serum tumor markers and enhance immune function,prolong median survival and improve the patients'quality of life.
万方数据
维普
